Available Monotherapies and Combination Therapies in mCSPC

"The test is fast, minimally invasive and cost-effective, and opens up a new suite of tools that will help us optimize treatment and quality of life for prostate cancer patients,” said Edwin Posadas, MD.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

“If there is such a clear difference between what different physicians are recommending, that calls into the need for patients to be more involved in decisions,” says Angela Fagerlin, PhD.

“The current landscape of online materials about prostate cancer is generally pretty bleak,” says Stacy Loeb, MD, PhD, MSc.

FACT-RNT is the first tool to measure patient reported outcomes associated with radionuclide therapy for prostate cancer.

The double-blind phase 3 KEYNOTE-991 trial had enrolled 1251 patients.